June 2017 Newsletter
Social Media and the ELCC
Anne-Marie Baird - Senior Research Fellow, St. James’s Hospital, Dublin
Last month nearly 2,000 delegates from over 80 nations attended the European Lung Cancer Conference in Geneva, Switzerland (May 5–8). The conference was organized by the IASLC (@IASLC) and ESMO (@myESMO), in partnership with ESTRO (@ESTRO_RT), ESTS (@thoracic) and ETOP (@ETOP_eu). The official conference hashtag, #ELCC17, was registered with www.symplur.com, which allows for the generation of transcripts and analytics.
During the course of the conference nearly 2,000 tweets created almost five million impressions from over 500 participants. The average number of tweets per participant was three. Those contributing to the dynamic conversation came from all over the world and included (amongst others) patients and advocates; medical and radiation oncologists; surgeons, pathologists and scientists; as well as cancer societies and pharma. Other social media channels used during the conference included Instagram and Facebook. Registering and promoting the use of a conference hashtag provides an important resource for patients, advocates and other medical professionals who are unable to attend a meeting, or indeed attendees who may miss talks due to the concurrent nature of conference sessions.
If you would like to find out what happened at the ELCC or where you ranked in mentions or impressions, check out https://www.symplur.com/healthcare-hashtags/elcc17/. Don’t forget to select the appropriate dates at the bottom of the page!
June 2017: The IASLC and the Journal of Thoracic Oncology (JTO) are pleased to present the Editor's Choice each month to highlight certain articles of interest. The articles below from the June 2017 issue of the JTO are free for three months. Please share with your colleagues around the globe!
Alex A. Adjei, MD, PhD
Use of Stereotactic Ablative Radiotherapy (SABR) in Non-Small Cell Lung Cancer Measuring More Than 5cm
By Tekatli et al.
Long-Term Outcomes of Salvage Stereotactic Ablation Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial
By Chang et al.
Bradley and colleagues have composed a thoughtful editorial that accompanies both SABR articles.
Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma
By Rimner et al. Their findings are discussed further in an editorial by Dr. Harvey Pass.
Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape
By Farukhi et al. Banerji and colleagues put their findings into a broader context in the accompanying editorial.
The following article was selected from the JTO by the IASLC Communications Committee to be promoted to the media and the public with a press release that was released at the time of online publication (published ahead of print).
To read more IASLC press releases, please visit the IASLC Research Articles. These press releases are also announced via social media, so please follow the IASLC on Twitter, LinkedIn and Facebook to stay up to date on the latest scientific topics. Also, please follow the JTO on Twitter and Facebook.
IASLC announces the second annual publication of “Scientific Advances in Thoracic Oncology,” available online now and in the August 2017 issue of the IASLC’s Journal of Thoracic Oncology (JTO).
All members whose membership expired on December 31, 2016, will receive member renewal notices. If you chose a multi-year membership in 2016, your membership will continue uninterrupted.
The IASLC is continuing the three-year registration options for all categories (except complimentary Fellow Membership). Our three-year option "locks-in" the current membership rates. Regular members will save $150.00 over three years by selecting the three-year membership option ($600.00). Developing Country Members and Allied Health Professionals can avoid potential future increases and don't have to renew each year.
We encourage all members to renew to ensure that there is no interruption of benefits such as JTO delivery and online access. Please review the single-year and multi-year options available to you!
Thinking about joining the IASLC as a new member? Watch the video below to understand why the IASLC is an organization like no other!
Member Directory Currently in Development
Additionally, we are asking for your delivery preference; unless you opt-in to receive the print version of the IASLC Member Directory, which is mailed to members at no charge, you will have access to the online searchable directory. Please be on the lookout for this email from the IASLC. If you do not receive this email, please contact email@example.com.
2016 Lung Cancer Awareness Month Survey
In early 2016, the IASLC proposed a common strategy for Lung Cancer Awareness Month (LCAM) that was designed to unify the public awareness efforts of all lung cancer organizations and to augment the community's collective impact. It was agreed that the IASLC was in a unique position to lead this unified effort among advocacy organizations.
The LCAM campaign was supported by independent educational grants from Merck & Co., Inc., Eli Lilly and Company and Helsinn. To help with our planning efforts for the 2017 LCAM initiative, please take a moment to complete the following survey to provide feedback about your participation with the 2016 LCAM campaign.
Become a Member
Join the only international association solely dedicated to lung cancer research and treatment.
WCLC Virtual Library
October 15 - 18 2017Yokohama, Japan
Fifth AACR-IASLC International Joint Conference on Lung Cancer Translational Science: From the Bench to the ClinicJanuary 8 - 11 2018San Diego, California
February 21 - 24 2018Santa Monica, California